Navigation Links
ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO

as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the outcome of the Company's research and clinical development processes; the outcome of the Company's collaboration partners' research and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense and results of preclinical studies and clinical trials; the Company's dependence on collaborative partners; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2006 and other reports filed with the Securities and Exchange Commission.

Contact

Investors:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations
and Corporate Communications
info@immunogen.com
or
Media:
KMorrisPR
Kathryn Morris, 845-635-9828
Kathryn@kmorrispr.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... needle is a hollow needle commonly used with a ... to extract fluids from it. A hypodermic needle is ... substances that cannot be ingested. Hypodermic needles are broadly ...
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... C Therapies Provides ... Clinical Practice, MILAN, Italy, April 26 Final ... study comparing the,leading therapies for chronic hepatitis C, were ... Association for the Study of the Liver,(EASL), providing important ...
Cached Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:7/11/2014)... Biostimulants are widely applied in turf ... ornamentals. These also help turf and ornamentals in absorption ... Turf, ornamentals, and flowers appear healthy and strong as ... increased from the last few years. The most dominating ... Europe, with around 40% share in 2013, and is ...
(Date:7/11/2014)... and overweight firefighters are not receiving weight management ... new research from The University of Texas Health ... state that health care professionals (HCPs) should advise ... weight. Firefighters have high rates of obesity, and ... deaths in firefighters. This study assessed the association ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... from the worldwide scourge of dengue fever was somewhat successful ... only prevented dengue fever in 56 percent of the 10,000 ... protected more than 88 percent of them from severe disease. ... and sometimes death. "This vaccine has already proven to ...
(Date:7/11/2014)... VA (PRWEB) July 11, 2014 Riverside Health ... Care (CBCC) in Virginia in late 2012 and now, ... ChooseHome – to residents throughout the Williamsburg and Newport News ... programs provide services and benefits to independent older adults who ... access to a safety net of continuing care services as ...
(Date:7/11/2014)... 11, 2014 Pigments are insoluble colorants, ... three functions namely protective coating, opacity, and coloring. These ... that impart color to substances such as paper, paints, ... pigments, which upon application impart color to the substance. ... carbon black, and hematite. , The coloring action of ...
Breaking Medicine News(10 mins):Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... Acquisition Will Extend Product Offering to Healthcare Customers, ... CLAI), a leading provider of electronic transaction services ... entered into an agreement,to acquire substantially all the ... The agreement is subject to due diligence and ...
... DES MOINES, Iowa, Dec. 13 If Congress passes,legislation ... authority,to regulate tobacco products, the new law would save ... keeping 25,700 kids from,becoming new smokers, according to a ... Senator Tom Harkin is a cosponsor of the,legislation. Senator ...
... part of St. Josephs Health Care, London and a ... at The University of Western Ontario. His team ... thousand Canadian peacekeeping veterans with service-related disabilities. The ... served with the Canadian Forces from 1990 to 1999. ...
... publishers, will begin publishing La Chirurgia degli Organi de ... is the official publication of the Istituti Ortopedici Rizzoli, ... It is published three times a year entirely ... Musculoskeletal Surgery, founded in 1917 at the Istituti ...
... COLUMBIA, Mo. Researchers from the University of Missouri ... vaccines directed against the virus that causes AIDS and ... published in the Dec. 14 edition of The Journal ... than a decade, Gary Clark, associate professor of Obstetrics, ...
... 13, 2007 Schizophrenia is one of the most debilitating ... the most difficult to treat. Although numerous antipsychotic treatments ... patients experience only a partial relief of their symptoms and ... new study scheduled for publication in the December 15th issue ...
Cached Medicine News:Health News:Claimsnet to Acquire Acceptius 2Health News:New Report: Tobacco Regulation Would Save Iowa $449 Million in Health Care Costs by Preventing 25,700 Kids from Smoking 2Health News:New Report: Tobacco Regulation Would Save Iowa $449 Million in Health Care Costs by Preventing 25,700 Kids from Smoking 3Health News:New study suggests why vaccines directed against cancer, HIV don't work 2Health News:Effective new treatment for schizophrenia 2